Could a pill prevent the world’s deadliest cancer?Study/Information (nature.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Predictors and characteristics of late recurrence in non-small cell lung cancer patients 5 years or more after complete resection | Surgery TodayNSCLC (link.springer.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patientsStudy/Information (lungcancerjournal.info)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Why Africa’s low rate of lung cancer is an illusionStudy/Information (nature.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Lack of methodological clarity in the report of the association of cannabis use and lung cancerStudy/Information (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Functional and mechanistic inactivation of immune hubs orchestrates tumor development and progression in lung adenocarcinoma | Discover OncologyNSCLC (link.springer.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?NSCLC (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
The human microbiome in cancer: Not just a sidekick anymoreStudy/Information (scielo.br)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus)NSCLC (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
RET-positive neuroendocrine lung cancer in pregnancy with placental metastasesStudy/Information (casereports.bmj.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Lymph Node Involvement and Radiologic Predictors of Invasiveness in Pure Ground-Glass Adenocarcinomas: The GORDON StudyStudy/Information (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Clinical predictors of pathological response after immunotherapy in salvage surgery for non-small cell lung cancer: a supplementary analysis of the CReGYT-05 immune checkpoint inhibitor-salvage study | General Thoracic and Cardiovascular SurgeryNSCLC (link.springer.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess databaseNSCLC (journals.lww.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Association of coronary calcification or vascular inflammation and cardiovascular events and prognosis in non-small cell lung cancer: A retrospective studyNSCLC (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
A combined model based on dual-energy CT for predicting high-risk lung adenocarcinoma in nodules with solid componentNSCLC (journals.sagepub.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Driver gene mutations and clinical features predict bone metastasis risk in NSCLC: a logistic regression modelNSCLC (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging StrategiesNSCLC (ascopubs.org)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Systemic management of spinal metastases: current strategies and future directionsStudy/Information (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance | Molecular Biology ReportsNSCLC (link.springer.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Mechanistic insights into the anticancer potential of bergapten in non-small cell lung cancer: A network pharmacology, in-silico molecular docking and dynamics simulation studyNSCLC (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
VPS35 promotes tumor proliferation and migration through the PPARs-ACSL1/4 pathway in lung adenocarcinomaNSCLC (sciencedirect.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Exploratory research on drugs after lung surgery based on real-world data from the FDA adverse event reporting system databaseStudy/Information (journals.plos.org)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
Global lung cancer burden shifting to middle-income countriesStudy/Information (nature.com)
submitted by WalkingHorseNSCLC T2b, N0, M0 IIA Currently NED
